Ipsen S.A.-Product Pipeline Review-2015

Ipsen S.A.-Product Pipeline Review-2015

  • Products Id :- GMDHC07171CDB
  • |
  • Pages: 58
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Ipsen S.A.-Product Pipeline Review-2015


Global Markets Direct's, 'Ipsen S.A.-Product Pipeline Review-2015', provides an overview of the Ipsen S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ipsen S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Ipsen S.A. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Ipsen S.A.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Ipsen S.A.'s pipeline products

Reasons To Buy

Evaluate Ipsen S.A.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Ipsen S.A. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Ipsen S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Ipsen S.A. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ipsen S.A.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Ipsen S.A. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Ipsen S.A. Snapshot 6

Ipsen S.A. Overview 6

Key Information 6

Key Facts 6

Ipsen S.A.-Research and Development Overview 7

Key Therapeutic Areas 7

Ipsen S.A.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products-Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

Ipsen S.A.-Pipeline Products Glance 16

Ipsen S.A.-Late Stage Pipeline Products 16

Pre-Registration Products/Combination Treatment Modalities 16

Phase III Products/Combination Treatment Modalities 17

Ipsen S.A.-Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

Ipsen S.A.-Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

Ipsen S.A.-Drug Profiles 22

abobotulinumtoxin A 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

lanreotide acetate 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

abobotulinumtoxin A next generation 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

triptorelin pamoate PR 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

BN-82451 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

BIM-23A758 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Peptides for Endocrine Gland Disorders 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Peptides for Oncology and Genito Urinary System And Sex Hormones 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Peptides to Antagonize ACTH Receptor for Cushing's Syndrome 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Recombinant Protein 1 to Inhibit SNARE for Neurology 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Recombinant Protein 2 to Inhibit SNARE for Neurology 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

STX-140 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

STX-681 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

SXN-101742 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

SXN-101959 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Drugs to Antagonize Androgen Receptor for Prostate Cancer 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Peptides for Endocrine Disease 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Ipsen S.A.-Pipeline Analysis 42

Ipsen S.A.-Pipeline Products by Target 42

Ipsen S.A.-Pipeline Products by Route of Administration 43

Ipsen S.A.-Pipeline Products by Molecule Type 44

Ipsen S.A.-Pipeline Products by Mechanism of Action 45

Ipsen S.A.-Recent Pipeline Updates 46

Ipsen S.A.-Dormant Projects 51

Ipsen S.A.-Discontinued Pipeline Products 52

Discontinued Pipeline Product Profiles 52

BIM-23A760 52

(mecasermin + somatropin) 52

irosustat 52

taspoglutide 52

Ipsen S.A.-Company Statement 53

Ipsen S.A.-Locations And Subsidiaries 54

Head Office 54

Other Locations & Subsidiaries 54

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

Ipsen S.A., Key Information 6

Ipsen S.A., Key Facts 6

Ipsen S.A.-Pipeline by Indication, 2015 8

Ipsen S.A.-Pipeline by Stage of Development, 2015 10

Ipsen S.A.-Monotherapy Products in Pipeline, 2015 11

Ipsen S.A.-Partnered Products in Pipeline, 2015 12

Ipsen S.A.-Partnered Products/ Combination Treatment Modalities, 2015 13

Ipsen S.A.-Out-Licensed Products in Pipeline, 2015 14

Ipsen S.A.-Out-Licensed Products/ Combination Treatment Modalities, 2015 15

Ipsen S.A.-Pre-Registration, 2015 16

Ipsen S.A.-Phase III, 2015 17

Ipsen S.A.-Phase II, 2015 18

Ipsen S.A.-Phase I, 2015 19

Ipsen S.A.-Preclinical, 2015 20

Ipsen S.A.-Discovery, 2015 21

Ipsen S.A.-Pipeline by Target, 2015 42

Ipsen S.A.-Pipeline by Route of Administration, 2015 43

Ipsen S.A.-Pipeline by Molecule Type, 2015 44

Ipsen S.A.-Pipeline Products by Mechanism of Action, 2015 45

Ipsen S.A.-Recent Pipeline Updates, 2015 46

Ipsen S.A.-Dormant Developmental Projects,2015 51

Ipsen S.A.-Discontinued Pipeline Products, 2015 52

Ipsen S.A., Subsidiaries 54

List of Figures

Ipsen S.A.-Pipeline by Top 10 Indication, 2015 8

Ipsen S.A.-Pipeline by Stage of Development, 2015 10

Ipsen S.A.-Monotherapy Products in Pipeline, 2015 11

Ipsen S.A.-Partnered Products in Pipeline, 2015 12

Ipsen S.A.-Out-Licensed Products in Pipeline, 2015 14

Ipsen S.A.-Pipeline by Top 10 Target, 2015 42

Ipsen S.A.-Pipeline by Top 10 Route of Administration, 2015 43

Ipsen S.A.-Pipeline by Top 10 Molecule Type, 2015 44

Ipsen S.A.-Pipeline Products by Top 10 Mechanism of Action, 2015 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of Ipsen S.A.; Ipsen S.A. - Key Therapeutics; Ipsen S.A. - Pipeline Overview and Promising Molecules; Ipsen S.A. - News; Ipsen S.A. - Latest Updates; Ipsen S.A. - Pipeline; Ipsen S.A. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102135
Site License
USD 3000 INR 204270
Corporate User License
USD 4500 INR 306405



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com